Regen BioPharma
4700 Spring Street
Suite 304
La Mesa
California
91942
United States
Tel: 619-702-1404
Fax: 619-330-2328
Website: http://www.regenbiopharma.com/
151 articles with Regen BioPharma
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
1/23/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs, will be presenting at the Emerging Growth Conference on January 25, 2023.
-
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
1/20/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today the filing of a provisional patent application covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity.
-
Regen BioPharma, Inc. to address 2023 goals and company direction at the Emerging Growth Conference on January 11, 2023
1/9/2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.
-
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
12/19/2022
Regen BioPharma, Inc. and As 2022 comes to a close, I would like to highlight some our many accomplishments achieved this year and also to respond to the multiple queries regarding future business strategy and planning that we have received.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
12/12/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on December 14, 2022.
-
Regen BioPharma Appoints Two New Scientific Advisory Board Members
12/7/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced that Dr. Ravinder Reddy, a Professor of Radiology at the University of Pennsylvania and Dr. Mohammad Haris, an Associate Professor at the University of Pennsylvania have joined its Scientific Advisory Board.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022
11/28/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs) will be presenting at the Emerging Growth Conference on November 30, 2022.
-
Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic
11/18/2022
The company announced the first phase of the set of in vitro experiments designed to accomplish this validation was successful.
-
Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic
11/10/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)has recently discussed the use of CAR-T therapies in cancer treatment.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022
11/2/2022
Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) will be presenting at the Emerging Growth Conference on November 9, 2022 (https://emerginggrowth.com/conference/).
-
Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space
10/26/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year on multiple ways to improve CAR-T therapies currently being utilized in the treatment of cancers.
-
Regen BioPharma, Inc. Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer
10/5/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled " Enhancement of T Cell Homing to Tumors Through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion" with the United States Patent and Trademark Office.
-
This week, researchers delivered insights and breakthroughs in regenerative medicine, Long COVID, immuno-oncology and inflammatory diseases.
-
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy
9/19/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled "Dual Checkpoint Inhibitor Aptamer Based Therapeutics".
-
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy
9/13/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a series of phased experiments to begin the process of moving its CAR-T cell de-differentiation approach through pre-clinical validation.
-
Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors
8/25/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a specific type of modified T cell called "chimeric antigen receptor" (CAR) T cell.
-
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors
8/11/2022
Regen BioPharma, Inc. announced the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company's novel approach for enabling chimeric antigen receptor -T cell-based therapies to kill solid tumors through prevention of a process called "T cell exhaustion".
-
Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine
7/26/2022
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), announced today the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine.
-
Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio
3/16/2022
Regen BioPharma, Inc. has an extensive intellectual property portfolio consisting of granted patents, published applications and pending applications.
-
Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies
3/10/2022
Regen BioPharma, Inc. announced a program to accelerate the clinical development of its NR2F6 therapies.